Patient
SITE015-0116
completed Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE015 (POL) (Dr. Ito)
consented 2026-01-13
Adverse events
5
Serious AEs
0
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 5
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-12-30 (study day 159); relationship: not assessed
Grade 3 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-12-27 (study day 156); relationship: NOT RELATED
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-12-03 (study day 132); relationship: not assessed
Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-09-27 (study day 65); relationship: not assessed
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-08-14 (study day 21); relationship: not assessed
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.